Actinogen Medical Limited · ASX:ACW
Actinogen Medical — AusBiotech Invest 2014
11 slides from Actinogen Medical's conference presentation, Dec 3, 2014
Slide 1: Developing Xanamem for treatment of Alzheimer's Dementia
For personal use only Developing Xanamem™ for treatment of Alzheimer’s Dementia – A Therapeutic Area with Largest Potential Martin Rogers AusBiotech Invest – Crown Casino Melbourne 2014 Chairman @martinfrogers
Slide 2: Forward Statements
This presentation has been prepared by Actinogen Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment dec
Slide 3: Company Snapshot
⇝ Stock code ASX: ACW – market cap approximately A$20 million ⇝ Developing treatments for chronic degenerative neurological conditions For personal use only ⊚ One of the largest drug potential with an unmet medical need with Company Alzheimer’s dementia ⊚ American Alzheimer’s Association estimates a
Slide 4: Alzheimer's Disease & Dementia
For personal use only Alzheimer’s Disease & Dementia ⇝ Alzheimer’s dementia is a degenerative brain disease around loss of memory and also the loss of use and understanding of language ⇝ There is no known cure or treatment to slow progression of the disease ⇝ It takes a disastrous toll on not only t
Slide 5: Affects Cognitive Function
For personal use only Affects Cognitive Function Dementia is typically documented by poorer performance on neuropsychological tests which assess memory, general knowledge, language, abstract reasoning and the ability to perform certain tasks of minimal skill (i.e. ‘ Please draw a clock. Put the hour
Slide 6: Xanamem Lead Candidate
Xanamem™ For personal use only ⇝ Xanamem™ is a patented (year 2028 and above) inhibitor of 11β- Lead HSD1 – a novel target for AD Candidate ⇝ Prevents regeneration of Cortisol – a stress hormone. Evidence suggests chronic stress and high cortisol levels lead to formation of amyloid plaques and neura
Slide 7: Xanamem: How it Works? Pre-clinical proof of concept data
Pre-clinical proof of concept data ⇝ 11β-HSD1 in brain is inversely associated with cognitive decline ⇝ 11β-HSD1 knockout models are protected against age-related cognitive For personal use only impairment Xanamem™ ⇝ XanamemTM as small molecule inhibition of 11β-HSD1 improves cognition in ageing and
Slide 8: Pharmacological inhibition of HSD1 improves memory in humans
Pharmacological inhibition of HSD1 with XanamemTM improves memory in humans For personal use only Human Proof of *Replicated in 2 cohorts Concept % change Carbenoxolone 4weeks vs placebo Completed Administration of the 11β-HSD1 inhibitor XanamemTM Carbenoxolone improved verbal fluency (p < 0.01) aft
Slide 9: Xanamem Pharmacodynamics Phase I study (Single Dose)
XanamemTM Pharmacodynamics Phase I For personal use only study (Single Dose) XANAMEM™ Phase I SAD Study Average 24h Liver Inhibition Plasma ACTH * Pre-dose ANOVA 23 hrs Plasma ACTH (pg/ml) *p=0.06 post-dose Unary THFs / THE ANOVA * *p<0.01 80% inh 0 25 0 25 Dose(mg) Dose(mg) Maximal enzyme inhibitio
Slide 10: Clinical Development Steps
⇝ Confirmed stability of active pharmaceutical ingredient (API) For personal use only ⇝ Capsules been manufactured to support Phase I multiple Clinical ascending dose (MAD) study Development ⇝ Second Phase I (MAD) and fast-fed study to start early 2015 (6 months to complete) Steps ⇝ Phase I MAD stud
Slide 11: Contact Details
For personal use only Contact Details Head Office Level 10, 15-17 Young St Sydney, NSW 2000 Australia Telephone: +61 (02) 9251 5620 Email: info@actinogen.com.au